ADA: Anti-VEGF ‘Impressive’ in Sharpening Vision (CME/CE, with video)

by MedPage Today • 2011/06/28 • 0 Comments

SAN DIEGO (MedPage Today) -- The good news continues to roll in for ranibizumab (Lucentis) in diabetic macular edema with positive RIDE and RISE trial results.

Full Story →

← Mimetogen Pharmaceuticals Inc. Announces Positive Top Line Data From Phase II Clinical Trial Of MIM-D3 For Dry Eye Disease

ADA: Anti-VEGF ‘Impressive’ In Sharpening Vision →

Post navigation